Slavin M A, Gooley T A, Bowden R A
Fred Hutchinson Cancer Research Center, Seattle, Washington.
Transplantation. 1994 Oct 27;58(8):915-9. doi: 10.1097/00007890-199410270-00010.
Bronchoalveolar lavage (BAL) was performed between days 35 and 45 posttransplant in 37 marrow recipients without clinical or radiologic evidence of cytomegalovirus (CMV) pneumonia to determine if the presence of CMV or cellular characteristics was predictive of subsequent development of CMV pneumonia. Analysis of BAL fluid included culture and direct fluorescent antibody staining for CMV, total mononuclear cell count, lymphocyte count, and lymphocyte subsets. Patients were followed to day 110 after transplant for development of CMV pneumonia. Weekly cultures of blood, urine, and throat were also obtained. BAL was positive for CMV in 7 patients, of whom 3 developed CMV pneumonia. It was negative for CMV in 30 patients, of whom 7 developed CMV pneumonia. The positive and negative predictive values for detection of CMV in day 35-45 BAL were 43% and 78%, for CMV viremia 66% and 87%, and for detection of CMV in urine and throat 41% and 94%, respectively, for subsequent CMV pneumonia. In 9/10 patients who subsequently developed CMV pneumonia, excretion of CMV from BAL, blood, urine or throat preceded CMV pneumonia, and BAL was the earliest site of CMV excretion in all nine. Only one patient did not excrete before developing CMV pneumonia. In a stepwise logistic regression of risk factors for developing CMV pneumonia, only CMV viremia was significant (P = 0.002) although the total BAL mononuclear cell count approached significance (P = 0.053). The percentage of lymphocytes in BAL and CMV excretion in BAL, urine, and throat were not significant. The positive predictive value of BAL for subsequent CMV pneumonia was no greater than that of culture of urine and throat and less than that of viremia in our patients.
对37名骨髓移植受者在移植后35至45天进行支气管肺泡灌洗(BAL),这些受者无巨细胞病毒(CMV)肺炎的临床或影像学证据,以确定CMV的存在或细胞特征是否可预测随后CMV肺炎的发生。对BAL液的分析包括CMV培养和直接荧光抗体染色、总单核细胞计数、淋巴细胞计数及淋巴细胞亚群分析。对患者随访至移植后110天,观察CMV肺炎的发生情况。同时每周采集血、尿和咽拭子进行培养。7例患者BAL液CMV检测呈阳性,其中3例发生CMV肺炎。30例患者BAL液CMV检测呈阴性,其中7例发生CMV肺炎。对于预测随后发生CMV肺炎,移植后35 - 45天BAL检测CMV的阳性和阴性预测值分别为43%和78%,CMV病毒血症分别为66%和87%,尿和咽拭子检测CMV分别为41%和94%。在随后发生CMV肺炎的10例患者中,有9例在CMV肺炎发生前BAL液、血液、尿液或咽拭子中有CMV排出,且在这9例中BAL是CMV最早排出的部位。仅1例患者在发生CMV肺炎前无CMV排出。在CMV肺炎发生风险因素的逐步逻辑回归分析中,只有CMV病毒血症具有显著性(P = 0.002),尽管BAL液总单核细胞计数接近显著性(P = 0.053)。BAL液中淋巴细胞百分比以及BAL液、尿液和咽拭子中CMV排出情况均无显著性。在我们的患者中,BAL对随后CMV肺炎的阳性预测值不高于尿和咽拭子培养,且低于病毒血症检测。